Back

SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

31 August 2019 (11:54 - 12:12)
Organised by:
Congress Presentation Part of: New frontiers: SGLT2 inhibitors in cardiorenal disease Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Caroline Holm Noergaard

Aalborg University Hospital, Aalborg (Denmark)

4 More presentations in this session

Presentation thumbnail
State of the Art - SGLT2 inhibitors in cardiovascular disease
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
Doctor T. Zelniker (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
Doctor J. Udell (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists
Professor N. Sattar (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
New frontiers: SGLT2 inhibitors in cardiorenal disease

The Event

Event poster

ESC Congress 2019

31 August 2019 11:54 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources